Literature DB >> 6547741

Concentration-time course of niridazole and six metabolites in the serum of four Filipinos with Schistosoma japonicum infection.

C I Valencia, B A Catto, E H Fairchild, S B Wilson, N C Maramba, L T Webster.   

Abstract

Niridazole and six of its metabolites have been quantitated by high-pressure liquid chromatography in sera of four male Filipino patients with mild Schistosoma japonicum infections given single oral doses of niridazole (15 mg/kg) on two occasions 10 days apart. Of the five oxidative metabolites measured, 4-hydroxyniridazole and 4-ketoniridazole achieved the highest concentrations, reaching peak values of 0.9 +/- 0.3 microgram/ml of serum (mean +/- S.D., n = 4) and 0.7 +/- 0.1 microgram/ml of serum within 1 to 4 hr. 4-Ketoniridazole achieved peak serum levels 1 hr after the other oxidative metabolites in three of four patients and was the predominant metabolite in the serum of all patients 6 to 10 hr after dosing. By 24 hr, both 4-ketoniridazole and 4-hydroxyniridazole had largely disappeared from the serum. Niridazole and three other oxidative metabolites, 4,5-dihydroxyniridazole, 5-hydroxyniridazole and 4,5-dehydroniridazole, appeared within 1 hr in serum but failed to exceed 0.4 microgram/ml; none of these compounds were detected in the 24-hr serum samples. The pharmacokinetic pattern of niridazole and the oxidative metabolites showed marked interindividual variation but was quite reproducible in the same individual studied 10 days later. 1-Thiocarbamoyl-2-imidazolidinone was analyzed in serum samples by a different high-pressure liquid chromatographic procedure. This reductive metabolite attained maximal levels of 50 to 150 ng/ml of serum 6 to 12 hr after drug administration and remained at 40% or more of its peak concentration even after 24 hr.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6547741

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

1.  Susceptibility of Campylobacter species to niridazole.

Authors:  R M Bannatyne; M A Karmali; J Jackowski; M Roscoe
Journal:  Eur J Clin Microbiol       Date:  1986-12       Impact factor: 3.267

Review 2.  Clinical pharmacokinetics of anthelmintic drugs.

Authors:  G Edwards; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

3.  Antibacterial activity of niridazole against Salmonellae.

Authors:  R M Bannatyne; J Jackowski; R B Grant
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.